Sydney Vital is pleased to announce the awardees for round 5 of our research scholarships awards. Congratulations to all our awardees and those who applied. More details on our awardees found below:
Subash Adhikari from the Department of Biomedical Science at Macquarie University, has been awarded for his proposed research titled, ‘uPAR interference peptide (iPEP) antagonists of αvβ6·uPAR interaction as colorectal cancer (CRC) metastasis therapy leads’. He is supervised by Prof. Mark Baker.
Colorectal cancer (CRC) is the second most commonly diagnosed cancer in men and women across Australia. If detected in the early stages, CRC has more than 90% survival rate. If detected in the later stages, the chances of survival fall to just 11%. Subash aims to develop new treatments in cancer diagnosis and in turn save healthcare costs associated with treatment of advanced CRC.
Christopher Nahm, supervised by Dr Anubhav Mittal, Dr Viive Howell, Dr Emily Colvin, Clinical Prof. Jaswinder Samra and Prof. Thomas Hugh has been awarded for his research project titled, ‘A proteomic approach to the discovery of novel biomarkers for the accurate diagnosis and prognostication of patients with pancreatic ductal adenocarcinoma using SWATH-MS’. The administering institution is the Bill Walsh Translational Cancer Research Laboratory, Kolling Institute.
Due to late diagnoses and a lack of therapeutic targets, pancreatic cancer has a high mortality rate.Christopher aims to utilise a high-powered technique for the discovery of proteins which will, in the future, act as biomarkers for future development of tests in the early diagnosis and prognosis of pancreatic cancer.
Kyle Crassini has been awarded for his proposed research titled, ‘mRNA expression profiling of chronic lymphocytic leukaemia (CLL) cells from in vivo hypoxic microenvironmental niches; applications for in vitro research and clinical management’. He is supervised by Prof. Chris Ward, Prof Stephen Mulligan and Dr. Giles Best and the Northern Blood Research Centre at the Kolling Institute of Medical Research is the administrative institute.
Chronic lymphocytic leukaemia (CLL) is the most commonly diagnosed leukaemia in adults. Currently, treatment for CLL compromises of a combination of fludarabine, cyclophosphamide and rituximab (FCR) or an amalgamation of chlorambucil and obinutuzumab. One of Kyle’s research aims is to determine if the mRNA profile of CLL cells in the bone marrow correlates with clinical outcome of patients on a clinical trial of a fludarabine-based regimen.
Samuel Brennan, supervised by Dr Rosetta Martiniello-Wilks, has been awarded for his research project titled, ‘Development of a non-invasive liquid biopsy for prostate cancer: Identification of unique exosome microRNA (exomiR) signatures in patient body fluids for cancerdiagnosis and prognosis II’. The administering institute is UTS Translational Cancer Research Group (TCRG) School Life Sciences, University of Technology Sydney (UTS).
One in six Australian men will be diagnosed with prostate cancer in their lifetime. Samuel aims to develop a ‘non-invasive robust clinical real-time reverse transcription PCR test for patient serum or urine to improve the early and advanced prostate cancer diagnosis and prognosis.
Vincent Caillet has been awarded for his proposed research title, ”The world first clinical implementation of real-time lung cancer targeting using a conventional linear accelerator’. The administrative institution is the Radiation Physics Laboratory at the University of Sydney and he is supervised by Prof. Paul Keall and Dr Jeremy Booth.
In Australia, the five-year survival rate for lung cancer is only 14.4% and it is the leading cause of cancer death in both men and women worldwide. Vincent aims to improve quality of life and reduce radiation-induced toxicities in lung cancer patients by implementing a method to track the tumour during breathing.
To keep up-to-date with our scholarships and funding awards, keep an eye on our grant schemes.